

26 26 deprivation index), hospital admission or death within 28 days of infection were extracted for adults
27 (18+) diagnosed with either T1DM or T2DM.

28 Results: For T2DM, 16 to 20 medications (p=0.005; OR [95% CI]=2.375 [1.306 to 4.319]) and > 20 29 medications (p<0.001; OR [95% CI]=3.141 [1.755 to 5.621]) were associated with increased risk of 30 death following COVID-19 infection. Increased risk of hospital admissions in T2DM individuals was 31 associated with 11 to 15 medications (p=0.013; OR [95% CI]=1.341 [1.063 to 1.692]) and above. This 32 was independent of comorbidities, metabolic and demographic factors. For T1DM there was no 33 association of polypharmacy with hospital admission. Respiratory, cardiovascular/cerebrovascular 34 and gastrointestinal conditions were associated with increased risk of hospital admissions and 35 deaths in T2DM (p<0.001). 35 deaths in T2DM (p<0.001).
36 Conclusion: We have shown in T2DM an independent association of multiple medications taken

37 from 11 upwards with adverse health consequences following COVID-19 infection. We also found 38 that individuals with diabetes develop comorbidities that were common across both T1DM and 39 T2DM. This study has laid the foundation for future investigations into the way that complex 40 pharmacological interactions may influence clinical outcomes in people with T2DM. 41

42 42 Keywords: polypharmacy; comorbidity; electronic health records; COVID-19

43

44 Introduction 46 that led to the 2020 pandemic. COVID-19 infections can lead to adverse outcomes, such as hospital 47 admission or death, the risk of which are increased further for individuals diagnosed with either type 48 admission 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM)^{1,2}. Increased risk of adverse health 49 outcomes following COVID-19 infection have also been linked to other underlying medical 50 conditions, which has raised concerns for chronic disease care $3-7$. It has been showed that socially 51 marginalised and psychiatrically vulnerable individuals are at higher risk of severe health outcomes

following COVID-19 infection 8 . McQueenie et al. (2020) investigated the UK Biobank data to
53 determine the association between multi-morbidity (including polypharmacy as a proxy) and COVID-54 19 infection risk ⁹. McQueenie et al. (2020) reported that individuals diagnosed with \geq 2 55 cardiometabolic conditions and increasing polypharmacy were associated with increased the risk of 55 covid-19 infection⁹. S6 COVID-19 infection⁹.
57 Previous studies of COVID-19 in individuals with T1DM and T2DM (in the Greater Manchester (GM)

58 area) have shown that the prescribing of certain medications influenced the likelihood of 59 bospitalisation or death following COVID-19 infection $10,11$. Many individuals in this population are 60 often prescribed, and are taking, multiple medications as they live with other long-term conditions.

61 The definition of 'polypharmacy' has been shown to widely vary in the published literature 12 . In 62 addition to this term, Masnoon et al. (2017) summarised that the terms minor, moderate and major 63 polypharmacy were used in literature to describe when between 2 to 11 or more medications are 64 consumed. The most commonly reported number of medications across these 'polypharmacy' terms 65 was greater than or equal to 5, as identified in the review 12 .

66 It is widely accepted that the higher the number of medications prescribed and taken by an 67 individual, the higher the risk of poor health outcomes. Recent reviews have reported a high 68 prevalence of polypharmacy in older people diagnosed with diabetes and an association with several 69 health-related outcomes, including falls, syncope, hospitalization, and death, as well as highlighting 70 the need to reduce inappropriate prescribing $13-15$. Several studies have also investigated the 71 relationship between polypharmacy and severe COVID-19 health outcomes 16.17 . However, there is 72 little understanding of how polypharmacy in people with diabetes might affect their risk of severe 73 health outcome post COVID-19 infection, other than the public health burden and impact of adverse 74 drug-drug interactions in individuals 18 .

75 Electronic health records (EHR) emerged as a useful tool for public health and COVID-19 research, as 76 described by Madhavan et al. (2021) and Casey et al. (2016) $19,20$. It is also useful for improving health 76 described by Madhavan et al. (2021) and Casey et al. (2016) ^{19,20}. It is also useful for improving health
77 service for example by identifying and understanding health inequalities ^{21,22}. service for example by identifying and understanding health inequalities 22.2
77 .
2007 . The standing and when the predition inequalities 22.7

 $\overline{3}$

78 78 To date, there are no studies that explore the associations between both polypharmacy and
79 comorbidity with adverse health outcomes, such as hospital admission or death, post first infection 80 of COVID-19 specifically in individuals with diabetes. This retrospective cohort study aimed to 81 investigate whether polypharmacy independent of comorbidity conveys greater risk of adverse 82 outcomes in people with diabetes when testing positive for COVID-19 infection in UK EHR data. extending with diabetes when testing positive for COVID-19 infection in UK EHR data. In UK EHR data. In UK EHR
83

83 84 Materials and methods
85 Cohort data source

86 The Greater Manchester Care Record (GMCR) is an integrated database of primary care, secondary 87 care and mental health trusts from across GM (https://gmwearebettertogether.com/research-and-87 care and mental health trusts from across GM (https://gmwearebettertogether.com/research-and-88 planning/) for analyses covering a population of approximately 3 million people. Health and care
89 data were collected from 433 of 435 (99.5%) general practices in GM. Data were de-identified at 88 data were concern were collected from 433 of 435 (99.5%) general practices in GM. Data were de-incrementified at
90 source and were extracted from the GMCR database. This was a retrospective cohort study with the 90 source and were extracted from the GMCR database. This was a retrospective cohort study with the
91 period of follow-up 2020 to 2022 in relation to the main impact period of the COVID-19 pandemic. 91 period of follow-up 2020 to 2022 in relation to the main impact period of the COVID-19 pandemic.
92 The inclusion criteria for this study were defined as individuals that are registered with a GM GP 12 The includion criteria for this study were defined as individuals that are registered with a positive test
93 Practice and with a diagnosis of T1DM or T2DM and age 18 or above. Individuals with a positive test 93 practice and with a diagnosis of T1DM or T2DM and age 18 or above. Individuals with a positive test
94 for COVID-19 close to January 2020 were included in this study. The study included all people 94 for COVID-19 close to January 2020 were included in this study. The study included all people
95 diagnosed with diabetes and with data available in the GMCR in January 2020. No power calculation 96 was performed as we included all people with that diagnosis. 96 was performed as we included all people with that diagnosis.

98

98 Variables and data cleaning
99 Baseline demographic information (age, BMI, gender, ethnicity, smoking status, deprivation index), 100 bospital admission or death within 28 days of infection were extracted for adults (18+) diagnosed 101 with either T1DM or T2DM (the codes applied are summarised in Appendix 1). Other rare forms of 102 with either T1DM or T2DM (the codes applied are summarised in Appendix 1). Other rare forms of the codes appendix 102 with the codes appendix 102 with the codes were not included.

103 103 Hospital admissions were recorded within 4 weeks after, or 2 weeks before a positive COVID-19 test
104 (between Jan 2020 to May 2022). The exposure was defined as prescribed medications, which were 105 recorded in the EHRs and mapped to the corresponding BNF (British National Formulary) chapters. 106 For this study, medications were considered at a single point in time, the month closest to first 107 COVID-19 infection date (January 2020 onwards). The BNF groups were not mutually exclusive, 108 therefore medications that are grouped under more than one chapter were counted. History of 109 comorbidity was collected before March 2020.

110 Individuals who were not assigned a gender were excluded. A total of 410 individuals having a code 111 for both T1DM and T2DM were excluded. The study confounders were determined by literature 112 review. In studies using real world data analysis, a number of factors were not covered in the coded 113 data such as household makeup and employment. Links to the codes used for diabetes can be found 114 in the supplementary information. Data were checked for extreme outliers or inconsistent values 115 in the supprementary information. Data were checked for extreme outliers or inconsistent values
115 in and removed as appropriate.

the removed as a propriate.
116 Ethics

116 Ethics
117 This project was reviewed, and ethical approval for COVID-19 research was overseen by Health 118 Innovation Manchester and granted by the Greater Manchester Care Record (GMCR) review board 119 (ref: IDCR-RQ-046). This research was performed with anonymised data, in line with the Health 120 Research Authority's Governance arrangements for research ethics committees.

120 Research Authority's Governance arrangements for research ethics committees.

Statistical methods
122 Multivariable logistic regression analyses using a forward stepwise approach were performed on the 123 T1DM and T2DM individuals, measuring exposure to number of medications and comorbidities, with 124 either hospital admission or death after COVID-19 infection (within 28 days of COVID-19 diagnosis) 125 as the outcome. The models were adjusted for age, BMI, ethnicity, smoking status, IMD, eGFR <60 125 as the outcome. The models were adjusted for age, BMI, ethnicity, smoking status, IMD, eGFR
126 as mil/min/1.73m², cholesterol. HBA1C and blood pressure. Analyses were performed in STATA v17. This 126 ml/min/1.73m², cholesterol, HBA1C and blood pressure. Analyses were performed in STATA v17. This
127 manuscript follows the reporting recommendation of RECORD-PE ²³. 127 manuscript follows the reporting recommendation of RECORD-PE 23 .
128

129 Results

- 130 The study cohort included patients diagnosed as T1DM and T2DM separately. Across the Greater
131 Manchester Region a total of 145,907 individuals were diagnosed with T2DM and 9,705 were
-
- 132 diagnosed with T1DM (Table 1; Table 2). The number of deaths in T1DM were too low (n=30) for
- 133 further statistical analyses to explore the association with mortality. 133 further statistical analyses to explore the association with mortality.

134
135

135 Table 1. Baseline demographics of individual diagnosed with Type 1 diabetes (T1DM) or Type 2
136 diabetes (T2DM). diabetes (T2DM).

Beaths (within 28 days of committed infection) 30 (0.3) 885 (0.6) 885 (0.6)
egorical variables presented as N (%) and continuous variables as mean (±SD)
insend index: 1 denotes the least deprived and 5 the most deprived.
l

138 Cownsend index: 1 denotes the least deprived and 5 the most deprived.

139 * Medications prescribed close to January 2020.

140 * Closest point before first COVID-19 +ve test

141 * Estimated glomerular filtration rate * Medications prescribed close to January 2020.
140 the losest point before first COVID-19 +ve test
141 the stimated glomerular filtration rate
142 to Sodium glucose co-transporter 2 inhibitor (SGLT2i) or a glucagon-like p 140 t Closest point before first COVID-19 +ve test
141 t Estimated glomerular filtration rate
142 Sodium glucose co-transporter 2 inhibitor (SGLT
143 A varving number of multiple medications w 141 **Extracted glomerular filtration rate**
142 Sodium glucose co-transporter 2 inhibitor (SO
143 A varying number of multiple medications 142 ^{*} Sodium glucose co-transporter 2 inhi
143
144 A varying number of multiple med
145 1) A large proportion of individual

142 Sodium glucose co-transporter 2 inhibitor (SGLT2i) or a glucagon-like peptide 1 (GLP-1) agonist.
143 A varying number of multiple medications were prescribed to individuals with T1DM or T2DM (Table
145 A l. A large pro 143

1). A large proportion of individuals were prescribed between 1 to 5 medications; the distribution of

146 number of medications prescribed and BNF chapters can be seen in Figure S1 and Figure S2. In

147 T2DM, after endocrine and cardiovascular medications, the largest number of multiple prescriptions

148 were from the gastrointestinal (GI) BNF chapter.

149 Common comorbidities were grouped into broader categories (see Supplementary Information

150 Table S1) and counts were collated for T1DM and T2DM. The top six modal comorbidity groups 150 Table S1) and counts were collated for T1DM and T2DM. The top six model comorbidity groups

- 151 151 identified in T2DM were mental health conditions, hypertension, gastrointestinal or liver disease,
152 pain, respiratory conditions (or sinus-related) and cardiovascular/cerebrovascular conditions (Table
-
- 153 2). Of the individuals diagnosed with T2DM, 69.9% were diagnosed with hypertension and 44.9%
- 154 with mental health conditions (Table 2). The same six comorbidity groups were also identified in the
- 154 with mental health conditions (Table 2). The same six conditions groups were also identified in the
155 with dividuals with T1DM (Table S2). 156
- 156
157

157 Table 2. Prevalence of comorbidity groups in individuals diagnosed with T2DM. The top 6 groups 158 are shown in italics. $\frac{158}{\sqrt{158}}$

159
160

Learning of the univariate regression are reported
Confidence intervals) of the univariate regression are reported 160 Logistic Regression Analysis 161 Odds ratios (95% confidence intervals) of the universe

162 with T1DM and T2DM respectively.

- 163 tidm respectively.
-

T1DM
164 An increased risk of adverse outcomes post-infection was observed for individuals with T1DM and

- 165 GI/liver disorders (p<0.001; OR [95% CI] = 3.452 [2.118 to 5.625]) and pain associated conditions
- 166 (p=0.04; OR [95% CI] = 1.556 [1.021 to 2.372]) (Table 3). Age was determined as slightly protective of
- 167 hospital admission following COVID-19 diagnosis (p<0.001; OR [95% CI] = 0.964 [0.949 to 0.980]). $\frac{1}{2}$ hospital administration following $\frac{1}{2}$ diagnosis (pseudosis (pseudosis (pseudosis).

- 168 Other significant variables included eGFR < 60 (p<0.001; OR [95% CI] = 2.794 [1.746 to 4.47]). There
169 was no association with polypharmacy.
- 170

170
171 171 Table 3. Logistic regression analyses of hospital admission following COVID-19 diagnosis in
172 individuals with T1DM.

Variable	OR (95% CI)	p value
Age	0.964 (0.949 to 0.980)	< 0.001
Sex	0.792 (0.537 to 1.167)	0.239
BMI	0.989 (0.960 to 1.02)	0.485
Ethnicity		
Asian	0.919 (0.431 to 1.956)	0.826
Black	0.388 (0.052 to 2.882)	0.355
Mixed	1.889 (0.444 to 8.04)	0.390
Other	0.447 (0.108 to 1.852)	0.267
Unknown	0.250 (0.035 to 1.809)	0.170
Smoking status		
Current smoker	0.856 (0.487 to 1.507)	0.590
Ex-smoker	1.022 (0.665 to 1.571)	0.921
Unknown/missing	1.237 (0.285 to 5.359)	0.777
IMD		
2	0.865 (0.404 to 1.851)	0.708
3	0.65 (0.291 to 1.452)	0.294
4	0.999 (0.501 to 1.992)	0.998
5 (most deprived)	0.843 (0.441 to 1.61)	0.604
eGFR<60	2.794 (1.746 to 4.47)	< 0.001
Cholesterol	0.925 (0.780 to 1.097)	0.369
HBA1C	1.002 (0.993 to 1.011)	0.681
Systolic BP	0.998 (0.984 to 1.012)	0.788
Diastolic BP	1.018 (0.996 to 1.041)	0.105
Comorbidity groups		
Mental health disorder	0.690 (0.463 to 1.028)	0.068
Hypertension	1.179 (0.746 to 1.865)	0.480
GI/liver disorder	3.452 (2.118 to 5.625)	< 0.001
Pain	1.556 (1.021 to 2.372)	0.040
Respiratory/sinus conditions	0.986 (0.650 to 1.496)	0.948
Cardiovascular/cerebrovascular	1.327 (0.814 to 2.162)	0.257
Total number of medications		
1 to 5	1.001 (0.235 to 4.271)	0.999
6 to 10	2.139 (0.488 to 9.381)	0.313
11 to 15	2.496 (0.539 to 11.554)	0.242
16 to 20	3.577 (0.738 to 17.329)	0.113

The contraction and 95% confidence intervals from the logistic regression model of hospital a
COVID-19 diagnosis. post COVID-19 diagnosis.

The logistic regression model of hospital and hospital administration model of hospital and hospital administration model of hospital and hospital administration model of hospital and hospital adm

177 In individuals with T2DM, an increased number of medications, from 11 upwards was associated 178 with increased risk of hospital admission following COVID-19 infection (Table 4). Individuals 179 diagnosed with co-morbidities in the following morbidity groups had an increased likelihood of 180 hospital admission: mental health disorders (p=0.003; OR [95% CI] = 1.167 [1.054 to 1.292]); Gastro-181 intestinal/liver disorders (p<0.001; OR [95% CI] = 1.977 [1.741 to 2.245]); pain (p<0.001; OR [95% CI] 182 = 1.407 [1.265 to 1.564]); respiratory/sinus conditions (p<0.001; OR [95% CI] = 1.235 [1.115 to 183 1.369]) and cardiovascular/cerebrovascular conditions (p<0.001; OR [95% CI] = 1.443 [1.292 to 184 1.612]). People with T2DM and eGFR level <60 (p<0.001; OR [95% CI] = 1.431 [1.268 to 1.614]) also 185 had an increased risk of hospital admission, similarly HBA1C levels (p=0.009; OR [95% CI] = 1.004 186 [1.001 to 1.006]) were also at increased risk (Table 4).

187 Males were more likely to be admitted to hospital after infection with COVID-19 (p<0.001; OR [95% 188 CI = 1.312 [1.181 to 1.457]). High BMI was associated with a higher likelihood of adverse outcomes 189 (hospitalisation & mortality) from COVID-19 (p=0.002; OR [95% CI] = 1.011 [1.004 to 1.018]). Age was 190 protective of hospital admission; however the odds ratio was only slightly less than 1 (p=0.009; OR 191 [95% CI] = 0.993 [0.988 to 0.998]). Individuals of Asian (p=0.006; OR [95% CI] = 1.213 [1.058 to 1.39]) 192 or Black (p=0.003; OR [95% CI] = 1.441 [1.129 to 1.838]) ethnicities were also more likely to be 193 admitted to hospital following infection (Table 4).

194 Individuals who identified as 'current smokers' were not identified as being at increased risk 195 $(p< 0.001; OR [95\% CI] = 0.507 [0.419 to 0.614]).$ However, individuals who lived in areas with higher 196 social disadvantage were more likely to be admitted to hospital - IMD quintiles 4 and 5 (p=0.02; OR 197 [95% CI] = 1.278 [1.039 to 1.572]; p=0.033; OR [95% CI] = 1.236 [1.017 to 1.503]) (Table 4). 197 [95% CI] = 1.278 [1.039 to 1.572]; p=0.033; OR [95% CI] = 1.236 [1.017 to 1.503]) (Table 4).

198
199

199 Trable 4. Logistic regression analyses of hospital admission within 28 days of COVID-19 diagnosis in 200 Trable 4. Logistic regression analyses of hospital admission within 28 days of COVID-19 diagnosis in 200 individuals with T2DM.

and the station and 95% confidence intervals from the logistic regression model of hospital adm
https://www.com/intervals.com/intervals.com/intervals.com/intervals/intervals/intervals.com/intervals/interval
https://www.com 201 Odds ratios and 95% confidence intervals from the logistic regression model of hospital admission
202 post COVID-19 diagnosis.
203 In individuals with T2DM, the number of deaths was 885 (0.6% of the total number of ind

203
203 post Covid-19 diagnosis. The sumplement Covid-203
204 Post Covid and Table 1, An increased number of medications, from 16 to 20 to > 20 was
205 Post diagnosed with T2DM) (Table 1). An increased number of medication 203 205 diagnosed with T2DM) (Table 1). An increased number of medications, from 16 to 20 to > 20 was
206 associated with increased risk of death following COVID-19 infection (p=0.005; OR [95% CI] = 2.375 207 [1.306 to 4.319] and p<0.001; OR [95% CI] = 3.141 [1.755 to 5.621] respectively) (Table 5). 207 [1.306 to 4.319] and p<0.001; OR [95% CI] = 3.141 [1.755 to 5.621] respectively) (Table 5).

220 measure was <60 (p=0.011; OR [95% CI] = 1.382 [1.078 to 1.771]) (Table 5). 221

221
222 222 Table 5. Logistic regression analyses of deaths within 28 days of COVID-19 diagnosis in individuals 223 with T2DM.

)
Is ratios and 95% confidence intervals from the logistic regression model of mortality p
liagnosis. 224

226
227

226
227 Discussion 226
227 Discussion
... 227 Discussion

228 This study uniquely explored the relationship between number of medications and adverse outcome
229 From COVID-19 infection in individuals diagnosed with diabetes in the Greater Manchester 230 population and is therefore distinct from our previous published studies in this area 10,11 . We found 231 that the number of medications prescribed to an individual was associated with an increased risk of 232 severe outcome from COVID-19 infection, particularly in people living with T2DM (Table 4; Table 5). 233 Given the large proportion of individuals diagnosed with comorbidities, it was not unexpected that 234 Given any of these individuals were prescribed multiple medications (Figure S1; Figure S2). However, the 235 effect of multiple medications was independent of the presence of the most common comorbidities. 236 Polypharmacy, independent of other factors including major multimorbidity, was associated with an 237 increased likelihood of hospital admission in people with T1DM and of hospitalisation and death in 238 T2DM following COVID-19 infection. This has not been specifically reported previously, although it 239 was described in older individuals 24 . This is of relevance to the consequences following any serious 240 viral infection in people with diabetes, while also highlighting the importance of regular medicine 240 viral infection in people with diabetes, while also highlighting the importance of regular medicine

241 242 redications 25

242 medications ²⁵.
243 The mean ages of individuals diagnosed with T1DM or T2DM are similar to the mean ages of a 244 Swedish cohort investigated by 1 . In our study we also identified several co-morbidities that 245 increased the risk of adverse health outcome post COVID-19 infection. Similar co-morbidities were 246 identified for both individuals with T1DM and T2DM. Notably, we also identified that there were a 247 large proportion of diagnoses of mental health conditions in people with T2DM (Table 2), though the 248 highest number of diagnoses was observed in people with T1DM (Table S2). The relation between 249 highest physical health conditions and poor mental health is an area that is not fully understood. In addition 250 to this, the impact of polypharmacy is unknown.

251 The risk of hospital admission in current smokers was less than non-smokers. The reason for this 252 may be that people with multiple health issues and who are smokers may have stopped smoking in 253 the weeks or months before a COVID-19 infection and therefore not be deemed as a smoker at the 254 time of the COVID-19 infection and therefore not be deemed as a smooth before not be deemed as a smooth as a smooth as a smooth α 254 time of the COVID-19 infection.
255 Over-prescribing is an issue in the current healthcare system. Medication is routinely recorded,

256 therefore in clinical practice there is the potential to flag the number of medications prescribed to 257 clinicians to monitor. Thereby the number of prescriptions given to vulnerable individuals could be 258 limited as appropriate and effective for the individual, though this does require both routine 259 monitoring and structured reviews of the medications that people are taking. The UK healthcare 260 system looks to improve the management of prescriptions, and the removal of unnecessary 261 medications is key to reducing the burden of polypharmacy 26.27 .

262 One of the limitations of this study is that a measure of 'frailty' was not included 28 . However, a 263 count of comorbidities is included which could possibly be used as a proxy for frailty. As the data 264 from this study originated from electronic health records, it is also subject to the limitations of how 265 information is coded when originally entered into the systems, such as missing data. Only 70% of 266 individuals with T1DM were recorded with a prescription of insulin (Table 1), this could be due to 2666 individuals with T1DM were recorded with a prescription of insulin (Table 2_p , this could be due to

267 267 lack of recording or unclear diagnosis, which highlights another issue with routinely collected data.
268 Another issue is that medications are recorded in the health care records are not true reflections of 269 Another is that are concordant with the choices of the individual 29 . A study in the United States 270 demonstrated that EHR-related medication errors can occur at different stages including at ordering. 271 preparation, dispensing, administering or monitoring stage, these can ultimately affect the data in 272 EHRs³⁰. Inaccuracies of coding are inherent in any project that relies on primary coded data. 273 Nevertheless, the large number of people included in the study means that such inaccuracies are 274 unlikely materially to influence the results. Furthermore, medications can also be counted in more 275 than one BNF chapter, making it difficult to determine unique counts. As this data was from one 276 region in the UK, it is difficult to generalise to the rest of the population. Finally in studies using real 277 world data analysis, there will be a number of factors that are not covered in the coded data such as 278 household makeup and employment.

279 Future work would include investigating the modal medications prescribed in this cohort and explore 280 possible drug-drug interactions between medications that could contribute to increasing the risk of 281 adverse outcome post COVID-19 infection. The burden of mental health conditions on people with 282 diabetes and how to effectively manage multiple long-term conditions, could also be explored. The 283 knowledge gained would be useful for future pandemics and better prepare our healthcare system.

284 In conclusion, we have identified that multiple medications were prescribed to many people living 285 with diabetes and that this was associated with a higher risk of adverse health outcome following 286 COVID-19 infection. We also found that individuals with diabetes also developed comorbidities that 287 were common across both Type 1 and 2 diabetes. Our analysis confirmed the impact of higher levels 288 of deprivation on increasing a person's a risk of adverse outcome post COVID-19 infection. This study 289 has laid the foundation for future investigations into the increased and complex treatments people 290 having with diabetes who develop other clinical complications. 290 living with diabetes who develop other clinical complications.

292 Acknowledgements
293 This work was supported by the Turing-Manchester Feasibility Project Funding. The authors 294 The Turing was the Greater Manchester Care Record (a partnership of Greater Manchester Health and 295 Social Care Partnership, Health Innovation Manchester and Graphnet Health, on behalf of Greater 296 Manchester localities) in the provision of data required to undertake this work. This work uses data 297 provided by patients and collected by the NHS as part of their care and support. GT was funded by 298 the NIHR Manchester Biomedical Research Centre (NIHR203308) for this work. DMA is supported by 299 the NIHR Greater Manchester Patient Safety Research Collaboration (PSRC). The views expressed are 300 those of the authors and not necessarily those of the NIHR or the Department of Health and Social 300 those of the authors and not necessarily those of the NIHR or the Department of Health and Social

$\frac{3}{202}$ Care 302 Author contributions

303 RR performed the data cleaning and data analyses. JG, WO and AHH conceived the study. JG
304 prepared the figures and the manuscript. GT extracted the original dataset. DM WO and AHH 305 contributed to all sections of the paper and DM provided expert input from a pharmacological 306 perspective. All authors were involved in designing the study, interpreting results and the reviewing 307 and editing of the manuscript.

307 and editing of the manuscript. 308 Conflicts of interest

309 Authors declare no conflict of interest.
3409 Authors declare no conflict of interests. 310 Data availability statement

- 311 The datasets generated during and analysed during the current study are not publicly available as all
312 data access is subject to review by Health Innovation Manchester.
-

312 Supplementary Materials 313 Supplementary Materials

- 314 Links to the clinical codes applied for diabetes diagnoses can be found in the 'methods' section of
315 the supplementary material file. Figure S1: distribution of medications prescribed in T1DM
- $\frac{1}{3}$ the supplementary material figure S1: distribution of medication preservation of medications preserve

- 316 316 individuals. Figure S2: distribution of medications prescribed in T1DM individuals. Table S1:
317 breakdown of comorbidity groups. Table S2: Prevalence of comorbidities groups in T1DM.
- 317 breakdown of comorbidity groups. Table S2: Prevalence of comorbidities groups in T1DM.

318 Preprint

319 A preprint has previously been published [31]. 320 References

- 321 1. Rawshani A, Kjölhede EA, Rawshani A, et al. Severe COVID-19 in people with type 1 and type 2
322 diabetes in Sweden: A nationwide retrospective cohort study. The Lancet Regional Health -
323 Europe. 2021:4:100105. d Europe. 2021;4:100105. doi:10.1016/j.lanepe.2021.100105
- 324 2. Izzi-Engbeaya C, Distaso W, Amin A, et al. Adverse outcomes in COVID-19 and diabetes: a 325 retrospective cohort study from three London teaching hospitals. BMJ Open Diabetes Res Care.
326 2021;9(1):e001858. doi:10.1136/bmjdrc-2020-001858 2021;9(1):e001858. doi:10.1136/bmjdrc-2020-001858
- 327 3. Kone AP, Martin L, Scharf D, et al. The impact of multimorbidity on severe COVID-19 outcomes 328 329 3. Kone Apple Apple Apple Apple D, and the international process of multimorphement of the internation
328 329 30:10.1016/i.dialog.2023.100128 328 in community and congregate settings. Dialogues in Health. 2023;2:100126.
329 doi:10.1016/j.dialog.2023.100128 doi:10.1016/j.dialog.2023.100128
330 4. Li Y, Ashcroft T, Chung A, et al. Risk factors for poor outcomes in hospitalised COVID-19 patients:
- 331 A systematic review and meta-analysis. J Glob Health. 11:10001. doi:10.7189/jogh.11.10001
- 332 5. Fekadu G, Bekele F, Tolossa T, et al. Impact of COVID-19 pandemic on chronic diseases care 333 follow-up and current perspectives in low resource settings: a narrative review. Int J Physiol
334 Pathophysiol Pharmacol. 2021:13(3):86-93. Pathophysiol Pharmacol. 2021;13(3):86-93.
- 335 6. Danhieux K, Buffel V, Pairon A, et al. The impact of COVID-19 on chronic care according to 336 beta providers: a qualitative study among primary care practices in Belgium. *BMC Family Practice.*
337 2020:21(1):255. doi:10.1186/s12875-020-01326-3 2020; 21(1): 255. doi: 10.1186/s12875-020-01326-3
- 338 7. Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: A systematic 339 literature review and meta-analysis. Journal of Infection. 2020;81(2):e16-e25.
340 doi:10.1016/i.iinf.2020.04.021 doi: 10.1016/j. jinf. 2020. 04. 021
- 341 8. Nilsson SF, Laursen TM, Osler M, et al. Adverse SARS-CoV-2-associated outcomes among people 342 experiencing social marginalisation and psychiatric vulnerability: A population-based cohort
343 study among 4,4 million people. The Lancet Regional Health - Europe. 2022;20:100421. 343 study among 4,4 million people. The Lancet Regional Health - Europe. 2022;20:100421.
344 doi:10.1016/j.lanepe.2022.100421 doi:10.1016/j.lanepe. 2022. 100421
- 345 9. McQueenie R, Foster HME, Jani BD, et al. Multimorbidity, polypharmacy, and COVID-19 infection 346 within the UK Biobank cohort. PLOS ONE. 2020;15(8):e0238091.
347 doi:10.1371/iournal.pone.0238091 doi:10.1371/journal.pone.0238091
- 348 10. Heald AH, Jenkins DA, Williams R, et al. The Risk Factors Potentially Influencing Hospital 349 Admission in People with Diabetes, Following SARS-CoV-2 Infection: A Population-Level Analysis.
350 Diabetes Ther. 2022;13(5):1007-1021. doi:10.1007/s13300-022-01230-2 350 Diabetes Ther. 2022;13(5):1007-1021. doi:10.1007/s13300-022-01230-2 350 Diabetes Ther. 2022;13(5):1007-1021. doi:10.1007/s13300-022-01230-2

- 389
- 389 24. Rahman S, Singh K, Dhingra S, et al. The Double Burden of the COVID-19 Pandemic and
390 Polypharmacy on Geriatric Population Public Health Implications. *Ther Clin Risk Manag.*
391 2020:16:1007-1022. doi:10.2147/
- 2020;16:1007-1022. doi:10.2147/TCRM.S272908
- 392 25. Kerr L. Polypharmacy in diabetes and solutions for greater adherence. Practical Diabetes 393 International. 2009;26(7):289-290i. doi:10.1002/pdi.1402
- 394 26. The ASHN Network. Polypharmacy. The AHSN Network. Published 2022. Accessed April 7, 2023. 395 https://www.ahsnnetwork.com/programmes/medicines/polypharmacy/
- 396 27. Department of Health and Social Care. National overprescribing review report. GOV.UK. 397 Published 2023. Accessed April 7, 2023. https://www.gov.uk/government/publications/national-
398 overprescribing-review-report
- 399 28. Hanlon P, Nicholl BI, Jani BD, Lee D, McQueenie R, Mair FS. Frailty and pre-frailty in middle-aged 300 and older adults and its association with multimorbidity and mortality: a prospective analysis of 401 and 493. 737 UK Biobank participants. The Lancet Public Health. 2018:3(7):e323-e332. 401 493 737 UK Biobank participants. The Lancet Public Health. 2018;3(7):e323-e332.
402 doi:10.1016/S2468-2667(18)30091-4 doi:10.1016/S2468-2667(18)30091-4
- 403 29. Marzec LN, Maddox TM. Medication Adherence in Patients with Diabetes and Dyslipidemia: 404 Associated Factors and Strategies for Improvement. Curr Cardiol Rep. 2013;15(11):418.
405 doi:10.1007/s11886-013-0418-7 doi:10.1007/s11886-013-0418-7
- 406 30. Carayon P, Du S, Brown R, Cartmill R, Johnson M, Wetterneck TB. EHR-related medication errors 407 in two ICUs. J Healthc Risk Manag. 2017;36(3):6-15. doi:10.1002/jhrm.21259
- 408 31. Gupta JK, Ravindrarajah R, Tilston G, Ollier W, Ashcroft DM, Heald AH. (2023). Association of
- 409 polypharmacy and burden of comorbidities on COVID-19 adverse outcomes in people with type 1 or
410 type 2 diabetes. MedRxiv. https://www.medrxiv.org/content/10.1101/2023.08.12.23294016v1.full
- 410 buybe 2 diabetes. Med Rxiv. https://www.medrxiv.org/content/10.1101/2023.08.12.23294016v1.full 410 type 2 diabetes. MedRxiv. <u>https://www.medrxiv.org/content/10.1101/2023.08.12.23294016v1.full</u>
411